Immunomodulation of glioma cells after gene therapy: induction of major histocompatibility complex class I but not class II antigen in vitro.
OBJECTIVE
Acquired immunity has been demonstrated in Fischer rats bearing syngeneic 9L tumors after herpes simplex virus (HSV) thymidine kinase (TK) gene transfection and ganciclovir treatment. The nature of this immunity in rats and its relevance to the HSV TK/ganciclovir protocol for human subjects remain to be determined. In this study, levels of major histocompatibility complex (MHC) Class I and II antigen expression were measured before and after HSV TK transfection, in an effort to document immunomodulatory changes caused by gene therapy.


METHODS
Tumor cells from the 9L gliosarcoma cell line, three primary human glioma cultures, and the human glioma cell line U87 MG were transduced with HSV TK vector-containing supernatant from fibroblast-producing cells (titer of 5 x 10(6) colony-forming units/ml) and selected in G418 medium for neomycin resistance. Clones were pooled or individually selected for cell-killing assays with ganciclovir, to confirm TK expression (10(3) cells/well in a 96-well dish). Northern analyses using MHC Class I and Class II complementary deoxyribonucleic acid probes were performed on blots containing total ribonucleic acid from wild-type tumor cells and HSV TK transfectants. A beta-actin complementary deoxyribonucleic acid probe served as an internal control. Cell surface expression was confirmed with flow cytometry. The induction of MHC Class I was tested for cycloheximide and genistein sensitivity.


RESULTS
All cell cultures exhibited increases in MHC Class I but not MHC Class II expression, as determined by Northern analysis densitometry and flow cytometry. Cycloheximide treatment did not diminish the up-regulation of MHC Class I after retroviral transfection, implicating a signal transduction pathway that does not require ongoing protein synthesis. Genistein pretreatment of cell cultures did diminish the up-regulation of MHC Class I, implicating a tyrosine kinase in the signaling cascade.


CONCLUSIONS
Induction of MHC Class I in rat and human glioma cells after HSV TK retroviral gene therapy is a primary effect that is dependent on tyrosine kinase activity. Specific immune responses generated after transfection may represent an important general side effect of gene therapy protocols. Elucidation of the mechanism of immunomodulation after gene therapy will likely yield safer and more effective clinical protocols.
Parsa
A T
AT
Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, Neurological Institute of New York, College of Physicians and Surgeons of Columbia University, New York, USA.
Chi
J H
JH
Hurley
P T
PT
Jeyapalan
S A
SA
Bruce
J N
JN
D000818:Animals; D016525:Antigenic Modulation / Q000235:genetics / Q000276:immunology; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D000954:Antigens, Surface / Q000235:genetics / Q000276:immunology; D015152:Blotting, Northern; D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy*; D005434:Flow Cytometry; D015870:Gene Expression / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D018316:Gliosarcoma / Q000276:immunology* / Q000628:therapy*; D066298:In Vitro Techniques; D008285:Major Histocompatibility Complex / Q000235:genetics* / Q000276:immunology*; D015213:Neuroimmunomodulation / Q000502:physiology*; D051381:Rats; D011916:Rats, Inbred F344; D018139:Simplexvirus / Q000201:enzymology / Q000235:genetics / Q000276:immunology; D013937:Thymidine Kinase / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014162:Transfection / Q000379:methods; D015854:Up-Regulation
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D013937:Thymidine Kinase